Janaky M, Braunitzer G
Vision (Basel). 2025; 9(1.
PMID: 39846623
PMC: 11755594.
DOI: 10.3390/vision9010007.
Schmitt V, Baeumler P, Schanzer A, Irnich D, Schoser B, Montagnese F
Front Neurol. 2024; 15:1414140.
PMID: 39193143
PMC: 11347447.
DOI: 10.3389/fneur.2024.1414140.
Forman T, Dennison B, Fantauzzo K
J Dev Biol. 2021; 9(3).
PMID: 34564083
PMC: 8482138.
DOI: 10.3390/jdb9030034.
Hofmeister F, Baber L, Ferrari U, Hintze S, Jarmusch S, Krause S
BMC Neurol. 2021; 21(1):241.
PMID: 34172001
PMC: 8229316.
DOI: 10.1186/s12883-021-02264-y.
Garcia-Moreno J, Romao L
Int J Mol Sci. 2020; 21(24).
PMID: 33321981
PMC: 7764535.
DOI: 10.3390/ijms21249424.
Dysregulation of Circular RNAs in Myotonic Dystrophy Type 1.
Voellenkle C, Perfetti A, Carrara M, Fuschi P, Renna L, Longo M
Int J Mol Sci. 2019; 20(8).
PMID: 31010208
PMC: 6515344.
DOI: 10.3390/ijms20081938.
Distribution and Structure of DM2 Repeat Tract Alleles in the German Population.
Mahyera A, Schneider T, Halliger-Keller B, Schrooten K, Horner E, Rost S
Front Neurol. 2018; 9:463.
PMID: 29973908
PMC: 6020772.
DOI: 10.3389/fneur.2018.00463.
High-throughput analysis of the RNA-induced silencing complex in myotonic dystrophy type 1 patients identifies the dysregulation of miR-29c and its target ASB2.
Cappella M, Perfetti A, Cardinali B, Garcia-Manteiga J, Carrara M, Provenzano C
Cell Death Dis. 2018; 9(7):729.
PMID: 29955039
PMC: 6023919.
DOI: 10.1038/s41419-018-0769-5.
Core Clinical Phenotypes in Myotonic Dystrophies.
Wenninger S, Montagnese F, Schoser B
Front Neurol. 2018; 9:303.
PMID: 29770119
PMC: 5941986.
DOI: 10.3389/fneur.2018.00303.
Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2.
Montagnese F, Mondello S, Wenninger S, Kress W, Schoser B
J Neurol. 2017; 264(12):2472-2480.
PMID: 29086017
DOI: 10.1007/s00415-017-8653-2.
Myotonic dystrophy: disease repeat range, penetrance, age of onset, and relationship between repeat size and phenotypes.
Yum K, Wang E, Kalsotra A
Curr Opin Genet Dev. 2017; 44:30-37.
PMID: 28213156
PMC: 5447468.
DOI: 10.1016/j.gde.2017.01.007.
Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1.
Perfetti A, Greco S, Cardani R, Fossati B, Cuomo G, Valaperta R
Sci Rep. 2016; 6:38174.
PMID: 27905532
PMC: 5131283.
DOI: 10.1038/srep38174.
Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism.
Meola G, Cardani R
J Neuromuscul Dis. 2016; 2(s2):S59-S71.
PMID: 27858759
PMC: 5240594.
DOI: 10.3233/JND-150088.
Identification of variants in MBNL1 in patients with a myotonic dystrophy-like phenotype.
Larsen M, Kress W, Schoser B, Hehr U, Muller C, Rost S
Eur J Hum Genet. 2016; 24(10):1467-72.
PMID: 27222292
PMC: 5027686.
DOI: 10.1038/ejhg.2016.41.
Myotonic disorders: A review article.
Hahn C, Salajegheh M
Iran J Neurol. 2016; 15(1):46-53.
PMID: 27141276
PMC: 4852070.
On the Applicability of Elastic Network Models for the Study of RNA CUG Trinucleotide Repeat Overexpansion.
Gonzalez A, Teixido J, Borrell J, Estrada-Tejedor R
PLoS One. 2016; 11(3):e0152049.
PMID: 27010216
PMC: 4806922.
DOI: 10.1371/journal.pone.0152049.
Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2).
Heatwole C, Johnson N, Bode R, Dekdebrun J, Dilek N, Hilbert J
Neurology. 2015; 85(24):2136-46.
PMID: 26581301
PMC: 4691689.
DOI: 10.1212/WNL.0000000000002225.
The Overlap between Fibromyalgia Syndrome and Myotonia Congenita.
Nam T, Choi S, Park D, Lee S, Kim Y, Kim M
J Clin Neurol. 2015; 11(2):188-91.
PMID: 25749817
PMC: 4387486.
DOI: 10.3988/jcn.2015.11.2.188.
Myotonic dystrophy.
Thornton C
Neurol Clin. 2014; 32(3):705-19, viii.
PMID: 25037086
PMC: 4105852.
DOI: 10.1016/j.ncl.2014.04.011.
Abnormal splicing of NEDD4 in myotonic dystrophy type 2: possible link to statin adverse reactions.
Screen M, Jonson P, Raheem O, Palmio J, Laaksonen R, Lehtimaki T
Am J Pathol. 2014; 184(8):2322-32.
PMID: 24907641
PMC: 4116696.
DOI: 10.1016/j.ajpath.2014.04.013.
